The company was established jointly by Zhongchong Group and Zhongchong Xinnuo Biotechnology (Taizhou) Co., Ltd. A total of RMB 148 million has been invested into a livestock and poultry vaccine production workshop of 15,000 square meters and an experimental animal housing of 5,000 square meters, including safety inspection area, result examining area and negative pressure toxic counteracting area for birds, pigs, rabbits, guinea pigs and mice.
Standardize the production of products to ensure the effectiveness of product quality, safety, uniformity, stability
In the new product research and development, "recombinant Newcastle disease virus inactivated vaccine (A-VII strain)" has received the certificate for first class national new veterinary drug; "Chicken Newcastle disease, infectious bronchitis combined live vaccine (La Sota strain + QXL87 strain", "Chicken Marek's disease gene-deficient live vaccine (SC9-1 strain)",
At the same time, the company is committed to technology research in disease diagnosis, prevention and control and purification, and undertakes the sub-project of national key research and development project - "breeding poultry farm Newcastle disease comprehensive prevention and control technology integration and demonstration research".
Add:No. 5 Taohongjing Road, Pharmaceutical High-tech Zone, Taizhou City, Jiangsu Province
Tel:0523-86202626
E-mail:zczy@czcg.com.cn